Fabrinet Free cash flow decreased by 102.4% to -$10.83M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 123.7%, from $45.67M to -$10.83M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 28.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $30.05M | $4.39M | $1.26M | $26.92M | $2.09M | $50.38M | $31.08M | $17.34M | $53.15M | $133.61M | $74.36M | $87.28M | $70.36M | $62.93M | $94.00M | $45.67M | $4.68M | $57.30M | -$5.35M | -$10.83M |
| QoQ Change | — | -85.4% | -71.2% | >999% | -92.2% | >999% | -38.3% | -44.2% | +206.5% | +151.4% | -44.3% | +17.4% | -19.4% | -10.6% | +49.4% | -51.4% | -89.7% | >999% | -109.3% | -102.4% |
| YoY Change | — | — | — | — | -93.1% | >999% | >999% | -35.6% | >999% | +165.2% | +139.3% | +403.3% | +32.4% | -52.9% | +26.4% | -47.7% | -93.3% | -8.9% | -105.7% | -123.7% |